Lyons-Williams Lori 4

What Happened
Lori Lyons‑Williams, a director of RAPT Therapeutics (RAPT), received an award of 4,956 restricted stock units (RSUs) on January 30, 2026. The grant was reported as an acquisition (code A) at a $0.00 per‑share price (total reported value $0). Per the filing, these RSUs represent contingent rights to receive one share of common stock each upon vesting and are part of the issuer’s non‑employee director compensation.

Key Details

• Transaction date: 2026-01-30 (reported on Form 4 filed 2026-02-02). Filing appears timely under the SEC two‑business‑day rule.
• Transaction type/code: Grant/Award (code A).
• Shares/units granted: 4,956 RSUs. Reported acquisition price: $0.00 (i.e., no cash paid).
• Vesting: RSUs fully vest on the first anniversary of the grant date (per footnote F1). Each RSU converts to one common share upon vesting.
• Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
• Footnote summary: Grant is the annual RSU award under the company’s Amended & Restated Non‑Employee Director Compensation Policy.

Context
Director RSU awards are a routine form of non‑cash compensation and do not represent an open‑market purchase or sale; they become meaningful if and when they vest and convert to shares. This grant alone should not be interpreted as a buy or sell signal; it primarily reflects standard director compensation.